<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02633930</url>
  </required_header>
  <id_info>
    <org_study_id>KY20151203-2</org_study_id>
    <nct_id>NCT02633930</nct_id>
  </id_info>
  <brief_title>Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Clarithromycin Quadruple Therapy</brief_title>
  <official_title>Helicobacter Pylori Eradication With Berberine Hydrochloride, Lansoprazole, Amoxicillin and Bismuth Versus Clarithromycin Bismuth, Lansoprazole and Amoxicillin: A Randomized, Open-label, Non-inferiority, Phase Ⅳ Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital of Digestive Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital of Digestive Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at evaluating efficacy and safety of berberine-containing quadruple
      therapy(berberine, lansoprazole, bismuth and amoxicillin) versus clarithromycin-containing
      quadruple therapy (clarithromycin,lansoprazole, bismuth and amoxicillin) in H. pylori
      eradication. It is hypothesized that berberine-containing quadruple therapy is non-inferior
      to clarithromycin-containing quadruple therapy. Patients with confirmed H. pylori positive
      status will be randomized to one of the treatments described above. At week 2 and 6 follow-up
      visits, a urea breath test(UBT) will be performed to confirm eradication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include three phases: screening, treatment and follow-up. Screening: this
      phase will last a maximum of 28 days and subjects eligibility will be evaluated after
      informed consent signature. Endoscopy and Urea Breath test will be performed in addition to
      the baseline routine evaluations.

      Treatment: Subjects are randomly assigned to treatment and will be treated for 14 days. A
      randomization visit will take place on Day 0 and an end-of-treatment visit will take place
      between day 12 and 14.

      Follow-up: includes two visits. approximately 14 days of treatment and 28 days after the end
      of treatment. Eradication of H. Pylori will be confirmed through urea breath test(UBT).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>helicobacter pylori eradication</measure>
    <time_frame>28 days after treatment</time_frame>
    <description>The primary end point of this study is H.pylori eradication,established by negative [13C] urea breath test 28 days after the end of eradication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>symptoms effective rates</measure>
    <time_frame>14 days of treatment, and 28 days after treatment</time_frame>
    <description>Evaluation effective rate of symptoms 2 weeks of treatment and 4 weeks after the end of treatment.
Symptom effective rate =（total score before treatment - total score after treatment）/total score before treatment x 100%. Total score = frequency + severity.
Frequency score is calculated by all the frequency of heartburn, reflux, abdominal pain, and flatulence. Severity is accumulated by the degree of symptoms described above, which is divided to 4 degree as 0 presenting none, and 3 presenting most severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>14 days of treatment, and 28 days after treatment</time_frame>
    <description>Participants with Adverse Events as a Measure of Safety and Tolerability.The common side effects of the study include headache, dizziness, skin rash, other gastrointestinal disorders, pyrexia, cough and back pain.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">566</enrollment>
  <condition>Gastritis</condition>
  <condition>Peptic Ulcer</condition>
  <condition>Dyspepsia</condition>
  <arm_group>
    <arm_group_label>berberine quadruple therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Berberine 300 mg, three times daily for 14 days,lansoprazole 30 mg,amoxicillin 1000 mg, and Bismuth 220 mg by mouth, twice daily for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>clarithromycin quadruple therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bismuth 220 mg, lansoprazole30 mg, amoxicillin 1000 mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Berberine</intervention_name>
    <description>: given for 14 days at a dose of berberine 100 mg 3 tablets TID, lansoprazole 30 mg BID, amoxicillin 500 mg 2 capsules BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID</description>
    <arm_group_label>berberine quadruple therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clarithromycin</intervention_name>
    <description>Clarithromycin-containing quadruple therapy group 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, lansoprazole 30mg 1tablet BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID.</description>
    <arm_group_label>clarithromycin quadruple therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bismuth</intervention_name>
    <description>Bismuth:given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, lansoprazole30 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID or given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, lansoprazole30 mg BID, amoxicillin 500 mg 2 capsules BID, and berberine 100 mg 3 tablet TID</description>
    <arm_group_label>berberine quadruple therapy</arm_group_label>
    <arm_group_label>clarithromycin quadruple therapy</arm_group_label>
    <other_name>Bitnal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole</intervention_name>
    <description>Lansoprazole 30mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 3 tablets TID given to berberine-containing quadruple therapy group or clarithromycin-containing quadruple therapy group</description>
    <arm_group_label>berberine quadruple therapy</arm_group_label>
    <arm_group_label>clarithromycin quadruple therapy</arm_group_label>
    <other_name>Takepron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amoxicillin</intervention_name>
    <description>Amoxicillin 500 mg 2 capsules BID plus lansoprazole 30mg 1tablet BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 3 tablets TID as a dose given for clarithromycin-containing quadruple therapy or berberine-containing quadruple therapy.</description>
    <arm_group_label>berberine quadruple therapy</arm_group_label>
    <arm_group_label>clarithromycin quadruple therapy</arm_group_label>
    <other_name>Amoxy ( Uni-Amocin )</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 18~70,both gender.

          2. Patients with upper gastrointestinal symptoms and with documented H.pylori infection.

          3. Patients are willing to receive eradication treatment.

          4. Women are eligible if they are not pregnant or nursing, and if they are of
             childbearing potential they are required to use medically acceptable contraception for
             the duration of the study and 30 days thereafter.

        Exclusion Criteria:

          1. Patients are excluded if they have previously used antibiotics to eradicate adequately
             recorded infection with H. pylori.

          2. Contraindications to study drugs.

          3. Substantial organ impairment, severe or unstable cardiopulmonary or endocrine disease.

          4. Constant use of anti-ulcer drugs ( including taking proton-pump. inhibitors(PPI)
             within 2 weeks before the [13C] urea breath test), antibiotics or bismuth complexes
             (more than 3 times /1 month before screening)

          5. Pregnant or lactating women.

          6. Underwent upper gastrointestinal Surgery.

          7. Patients with Barrett esophageal or highly atypical hyperplasia, have symptom of
             dysphagia.

          8. Evidence of bleeding or iron efficiency anemia.

          9. A history of malignancy.

         10. Drug or alcohol abuse history in the past 1 year.

         11. Systemic use of corticosteroids, non steroidal anti-inflammatory drugs,
             anticoagulants, platelet aggregation inhibitors (except the use of aspirin for less
             than 100 mg/d).

         12. Enrolled in other clinical trials in the past 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongquan Shi, Ph. D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xijing Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xijing Hospital of Digestive Diseases</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital of Digestive Disease</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2015</study_first_submitted>
  <study_first_submitted_qc>December 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2015</study_first_posted>
  <last_update_submitted>January 15, 2017</last_update_submitted>
  <last_update_submitted_qc>January 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xijing Hospital of Digestive Diseases</investigator_affiliation>
    <investigator_full_name>Yongquan Shi</investigator_full_name>
    <investigator_title>Doctor of Xijing Hospital of Digestive Diseases,Principal investagator,Clinical professor</investigator_title>
  </responsible_party>
  <keyword>helicobacter pylori</keyword>
  <keyword>berberine-containing quadruple therapy</keyword>
  <keyword>clarithromycin-containing quadruple therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
    <mesh_term>Peptic Ulcer</mesh_term>
    <mesh_term>Gastritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

